Zacks Research Analysts Reduce Earnings Estimates for Immunovant, Inc. (NASDAQ:IMVT)

Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities researchers at Zacks Research dropped their Q1 2026 EPS estimates for shares of Immunovant in a note issued to investors on Monday, April 8th. Zacks Research analyst E. Bagri now forecasts that the company will post earnings of ($0.49) per share for the quarter, down from their previous estimate of ($0.48). The consensus estimate for Immunovant's current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Immunovant's Q4 2026 earnings at ($0.55) EPS and FY2026 earnings at ($1.99) EPS.

A number of other research firms have also commented on IMVT. Cantor Fitzgerald reiterated an "overweight" rating on shares of Immunovant in a research report on Friday, January 12th. HC Wainwright boosted their price objective on Immunovant from $47.00 to $51.00 and gave the company a "buy" rating in a research note on Thursday, December 21st. Wolfe Research initiated coverage on shares of Immunovant in a research note on Thursday, February 15th. They set an "outperform" rating and a $55.00 target price on the stock. Oppenheimer initiated coverage on Immunovant in a research report on Thursday, March 28th. They set an "outperform" rating and a $50.00 target price on the stock. Finally, Truist Financial reaffirmed a "buy" rating and issued a $48.00 price target on shares of Immunovant in a research report on Monday, March 25th. Seventeen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $48.00.

Immunovant Stock Performance

Shares of NASDAQ:IMVT traded down $0.16 during mid-day trading on Thursday, reaching $30.72. 821,254 shares of the company's stock were exchanged, compared to its average volume of 1,229,242. The firm has a market capitalization of $4.46 billion, a price-to-earnings ratio of -16.78 and a beta of 0.65. Immunovant has a twelve month low of $14.11 and a twelve month high of $45.58. The business's fifty day moving average price is $33.88 and its 200-day moving average price is $36.35.

Immunovant (NASDAQ:IMVT - Get Free Report) last announced its quarterly earnings results on Monday, February 12th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07.

Hedge Funds Weigh In On Immunovant

Several institutional investors and hedge funds have recently bought and sold shares of the company. Los Angeles Capital Management LLC grew its holdings in Immunovant by 185.4% during the first quarter. Los Angeles Capital Management LLC now owns 14,371 shares of the company's stock valued at $464,000 after purchasing an additional 9,335 shares during the period. Wellington Management Group LLP grew its holdings in Immunovant by 75.0% during the fourth quarter. Wellington Management Group LLP now owns 295,020 shares of the company's stock valued at $12,429,000 after purchasing an additional 126,412 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Immunovant by 119.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,602,562 shares of the company's stock valued at $67,517,000 after purchasing an additional 872,520 shares during the period. GSA Capital Partners LLP bought a new position in Immunovant during the fourth quarter valued at $369,000. Finally, Blue Owl Capital Holdings LP bought a new position in Immunovant during the fourth quarter valued at $2,528,000. 47.08% of the stock is owned by institutional investors.

Insider Buying and Selling at Immunovant

In other news, CEO Peter Salzmann sold 4,807 shares of Immunovant stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $31.18, for a total transaction of $149,882.26. Following the sale, the chief executive officer now directly owns 1,086,958 shares in the company, valued at approximately $33,891,350.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Immunovant news, CFO Eva Renee Barnett sold 3,689 shares of the stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $31.18, for a total transaction of $115,023.02. Following the completion of the transaction, the chief financial officer now directly owns 371,709 shares of the company's stock, valued at $11,589,886.62. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Peter Salzmann sold 4,807 shares of the stock in a transaction on Tuesday, April 9th. The shares were sold at an average price of $31.18, for a total value of $149,882.26. Following the transaction, the chief executive officer now directly owns 1,086,958 shares of the company's stock, valued at $33,891,350.44. The disclosure for this sale can be found here. Insiders sold 18,064 shares of company stock worth $612,982 in the last quarter. 4.80% of the stock is currently owned by company insiders.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.